Nerofe

Generic Name
Nerofe
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C96H129N21O20
CAS Number
1311294-45-7
Unique Ingredient Identifier
SR717JCM7M
Background

Nerofe is under investigation in clinical trial NCT03059615 (A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS).

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

First Posted Date
2022-12-22
Last Posted Date
2024-03-12
Lead Sponsor
Georgetown University
Target Recruit Count
24
Registration Number
NCT05661201
Locations
🇺🇸

Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML

Phase 1
Recruiting
Conditions
AML
Advanced MDS
Interventions
Drug: Nerofe
First Posted Date
2020-04-28
Last Posted Date
2024-07-10
Lead Sponsor
Immune System Key Ltd
Target Recruit Count
18
Registration Number
NCT04365179
Locations
🇺🇸

University of Miami Hospital and Clinics / Sylvester Comprehensive Cancer Center, Miami, Florida, United States

A Phase 2a, Open-Label, Two Stage Study of Nerofe or Nerofe With Doxorubicin in Subjects With AML or MDS

First Posted Date
2017-02-23
Last Posted Date
2020-07-31
Lead Sponsor
Immune System Key Ltd
Registration Number
NCT03059615
Locations
🇮🇱

Kaplan Medical Center, Reẖovot, Israel

🇮🇱

Rabin Medical Center, Petach Tikva, Israel

Phase 1 Trial of Intravenously Administered Nerofeâ„¢ in Subjects With Advanced Malignancies

Phase 1
Completed
Conditions
Cancer
Interventions
Drug: Nerofe
First Posted Date
2012-09-24
Last Posted Date
2018-06-25
Lead Sponsor
Immune System Key Ltd
Target Recruit Count
23
Registration Number
NCT01690741
Locations
🇮🇱

Kaplan Medical Center, Rehovot, Israel

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy